Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.

Ward A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, Hielscher T, Wiemann S, Sahin Ö.

Oncogene. 2013 Feb 28;32(9):1173-82. doi: 10.1038/onc.2012.128. Epub 2012 Apr 16.

PMID:
22508479
2.

MiR-153 inhibits epithelial-mesenchymal transition by targeting metadherin in human breast cancer.

Li W, Zhai L, Zhao C, Lv S.

Breast Cancer Res Treat. 2015 Apr;150(3):501-9. doi: 10.1007/s10549-015-3346-y. Epub 2015 Mar 21.

PMID:
25794773
3.

MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3.

Li X, Wu Y, Liu A, Tang X.

Biochem Biophys Res Commun. 2016 Sep 2;477(4):768-773. doi: 10.1016/j.bbrc.2016.06.133. Epub 2016 Jun 27.

PMID:
27363334
4.

MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.

Ward A, Shukla K, Balwierz A, Soons Z, König R, Sahin O, Wiemann S.

J Pathol. 2014 Aug;233(4):368-79. doi: 10.1002/path.4363. Epub 2014 Jun 2.

5.

Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.

Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L, Coombes RC.

Breast Cancer Res. 2014 Jun 11;16(3):R62. doi: 10.1186/bcr3675.

6.

miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer.

Fu H, Fu L, Xie C, Zuo WS, Liu YS, Zheng MZ, Yu JM.

Oncol Rep. 2017 Feb;37(2):1093-1099. doi: 10.3892/or.2017.5360. Epub 2017 Jan 9.

PMID:
28075453
7.

MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.

Lü M, Ding K, Zhang G, Yin M, Yao G, Tian H, Lian J, Liu L, Liang M, Zhu T, Sun F.

Sci Rep. 2015 Mar 4;5:8735. doi: 10.1038/srep08735.

8.

Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.

Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y, Li H, Zhu X, Yao L, Zhang J.

Breast Cancer Res Treat. 2014 Sep;147(2):423-31. doi: 10.1007/s10549-014-3037-0. Epub 2014 Jul 10.

PMID:
25007959
9.

Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs.

Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP, White BA.

Breast Cancer Res Treat. 2012 Feb;132(1):75-85. doi: 10.1007/s10549-011-1534-y. Epub 2011 May 7.

PMID:
21553120
10.

miRNA-34a is associated with docetaxel resistance in human breast cancer cells.

Kastl L, Brown I, Schofield AC.

Breast Cancer Res Treat. 2012 Jan;131(2):445-54. doi: 10.1007/s10549-011-1424-3. Epub 2011 Mar 12.

PMID:
21399894
11.

Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.

Lin X, Li J, Yin G, Zhao Q, Elias D, Lykkesfeldt AE, Stenvang J, Brünner N, Wang J, Yang H, Bolund L, Ditzel HJ.

Breast Cancer Res. 2013 Dec 19;15(6):R119. doi: 10.1186/bcr3588.

12.

The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.

Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL, Ford CE.

BMC Cancer. 2013 Apr 2;13:174. doi: 10.1186/1471-2407-13-174.

13.

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA.

Mol Cancer Ther. 2012 Jul;11(7):1488-99. doi: 10.1158/1535-7163.MCT-11-0963. Epub 2012 May 7.

14.

Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer.

Zhang W, Qian P, Zhang X, Zhang M, Wang H, Wu M, Kong X, Tan S, Ding K, Perry JK, Wu Z, Cao Y, Lobie PE, Zhu T.

J Biol Chem. 2015 May 29;290(22):13812-29. doi: 10.1074/jbc.M115.653261. Epub 2015 Apr 14.

15.

MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.

Liao H, Bai Y, Qiu S, Zheng L, Huang L, Liu T, Wang X, Liu Y, Xu N, Yan X, Guo H.

Oncotarget. 2015 Apr 20;6(11):8914-28.

16.

MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells.

Han M, Wang Y, Liu M, Bi X, Bao J, Zeng N, Zhu Z, Mo Z, Wu C, Chen X.

Cancer Sci. 2012 Jun;103(6):1058-64. doi: 10.1111/j.1349-7006.2012.02281.x. Epub 2012 Apr 23.

17.

MTDH promotes glioma invasion through regulating miR-130b-ceRNAs.

Tong L, Chu M, Yan B, Zhao W, Liu S, Wei W, Lou H, Zhang S, Ma S, Xu J, Wei L.

Oncotarget. 2017 Mar 14;8(11):17738-17749. doi: 10.18632/oncotarget.14717.

18.

MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer.

Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL, Shen CY.

Breast Cancer Res Treat. 2012 Aug;134(3):1081-93. doi: 10.1007/s10549-012-2034-4. Epub 2012 Apr 4.

PMID:
22476851
19.

miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer.

Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, Dornan D.

PLoS One. 2013 Jun 11;8(6):e66502. doi: 10.1371/journal.pone.0066502. Print 2013.

20.

MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer.

Aydoğdu E, Katchy A, Tsouko E, Lin CY, Haldosén LA, Helguero L, Williams C.

Carcinogenesis. 2012 Aug;33(8):1502-11. doi: 10.1093/carcin/bgs161. Epub 2012 May 4.

PMID:
22562546

Supplemental Content

Support Center